Drug intelligence / Profile preview

eribulin + mifepristone

Development stage: Phase 1
Lead developer: Corcept Therapeutics
Modality: Small Molecules
Administration: Intravenous, Oral

Overview

A combination therapy consisting of eribulin, a microtubule inhibitor, and mifepristone, a glucocorticoid receptor (GR) antagonist. This novel combination is designed to improve antitumor activity in metastatic triple-negative breast cancer (TNBC) and other advanced solid tumors. Eribulin inhibits the growth phase of microtubules and sequesters tubulin into nonproductive aggregates, leading to G2/M cell-cycle block, disruption of mitotic spindles, and ultimately apoptotic cell death. Mifepristone acts as an antagonist of the glucocorticoid receptor, potentially enhancing the antitumor effects of eribulin.

Brand names: Mifegymiso
Other names: mifepristone + eribulin mesylate

Targets

GR (Glucocorticoid receptor)PR (Progesterone receptor)TUBB (Tubulin (alpha and beta subunits))

Beyond the preview

Go deeper on eribulin + mifepristone.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on eribulin + mifepristone.